Analysts’ Recent Ratings Updates for Bicara Therapeutics (BCAX)

Bicara Therapeutics (NASDAQ: BCAX) has recently received a number of price target changes and ratings updates:

• 8/21/2026 – Bicara Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/18/2026 – Bicara Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $35.00 price target on the stock.
• 8/18/2026 – Bicara Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 8/12/2026 – Bicara Therapeutics had its price target raised by Wedbush from $30.00 to $33.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Bicara Therapeutics had its price target raised by Mizuho from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – Bicara Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – Bicara Therapeutics had its price target raised by Wells Fargo & Company from $16.00 to $23.00. They now have an “equal weight” rating on the stock.
• 8/12/2026 – Bicara Therapeutics had its price target raised by BTIG Research from $28.00 to $39.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Bicara Therapeutics had its price target raised by Morgan Stanley from $37.00 to $39.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Bicara Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the sale, the chief financial officer owned 129,855 shares in the company, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the completion of the transaction, the chief operating officer directly owned 181,641 shares in the company, valued at $5,082,315.18. This trade represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 108,000 shares of company stock valued at $3,079,236. Company insiders own 13.80% of the company’s stock.

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.